What is the use for monoclonal antibodies in MPN?

During the 14th International Congress of Myeloproliferative Neoplasms, the MPN Hub was pleased to speak to Ann Mullally, Brigham and Women's Hospital, Boston, US. We asked, What is the use for monoclonal antibodies in myeloproliferative neoplasms (MPN)?

Mullally begins by summarizing preclinical studies on mutant calreticulin (CALR) as a target for monoclonal antibody (mAb) treatment in MPN. The unique altered sequence on mutant CALR makes it an ideal target for a mAb as unwanted effects on normal cells can be avoided. Mullally concludes by highlighting an oral communication in the upcoming 64th American Society Hematology Annual Meeting and Exposition, where we are going to learn more about the impact of these novel anti-mutant CALR mAbs on platelet count and cell growth in a mouse model.